ABVC BioPharma, Inc.
ABVC
$0.911
$0.0354.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 37.05% | 55.04% | 31.68% | 19.22% | 52.58% |
| Total Depreciation and Amortization | -47.19% | 1,290.51% | 1,345.08% | 1,406.83% | 1,498.32% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.93% | -26.32% | 29.34% | 39.34% | -66.93% |
| Change in Net Operating Assets | -183.21% | -127.58% | -114.18% | -65.65% | -22.78% |
| Cash from Operations | 56.79% | 58.60% | 2.83% | 46.42% | 43.41% |
| Capital Expenditure | -- | 100.00% | -371.11% | 20.00% | 82.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 126.75% | 104.97% | 78.84% | 78.84% |
| Cash from Investing | -- | 125.80% | 103.93% | 77.88% | 79.08% |
| Total Debt Issued | -33.56% | -71.00% | -140.58% | -141.10% | 317.89% |
| Total Debt Repaid | 69.99% | 63.44% | 81.35% | 81.35% | -- |
| Issuance of Common Stock | -6.81% | -14.08% | 656.80% | -73.20% | -73.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -84.51% | -79.05% | -- | -- | -- |
| Cash from Financing | -48.82% | -59.82% | 28.30% | -62.39% | -3.59% |
| Foreign Exchange rate Adjustments | -1,271.43% | -150.80% | -215.32% | 115.14% | 103.12% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 121.78% | 58.66% | 100.02% | 30.94% | 86.95% |